1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Amgen buying Onyx for $10.4 billion to be bigger player in cancer therapies

 
• By Brett Chase

Amgen said it will buy Onyx Pharmaceuticals for $10.4 billion in cash, or $125 a share, in a deal that significantly builds the big biotech company’s cancer drug program.

Amgen said it will buy Onyx Pharmaceuticals for $10.4 billion in cash, or $125 a share, in a deal that significantly builds the big biotech company’s cancer drug program.

Expected to close in the next couple of months, Amgen said the deal will add to earnings in 2015

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.